149 related articles for article (PubMed ID: 20097563)
21. Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.
Kishino H; Moriya M; Sakuraba S; Sakamoto T; Takahashi H; Suzuki T; Moriya R; Ito M; Iwaasa H; Takenaga N; Ishihara A; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Aug; 19(16):4589-93. PubMed ID: 19615899
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists.
Florjancic AS; Peddi S; Perez-Medrano A; Li B; Namovic MT; Grayson G; Donnelly-Roberts DL; Jarvis MF; Carroll WA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2089-92. PubMed ID: 18272366
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
Chao H; Turdi H; Herpin TF; Roberge JY; Liu Y; Schnur DM; Poss MA; Rehfuss R; Hua J; Wu Q; Price LA; Abell LM; Schumacher WA; Bostwick JS; Steinbacher TE; Stewart AB; Ogletree ML; Huang CS; Chang M; Cacace AM; Arcuri MJ; Celani D; Wexler RR; Lawrence RM
J Med Chem; 2013 Feb; 56(4):1704-14. PubMed ID: 23368907
[TBL] [Abstract][Full Text] [Related]
24. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M
J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835
[TBL] [Abstract][Full Text] [Related]
25. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization.
Post JM; Alexander S; Wang YX; Vincelette J; Vergona R; Kent L; Bryant J; Sullivan ME; Dole WP; Morser J; Subramanyam B
Thromb Res; 2008; 122(4):533-40. PubMed ID: 18539312
[TBL] [Abstract][Full Text] [Related]
26. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
[TBL] [Abstract][Full Text] [Related]
27. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
van Giezen JJ; Humphries RG
Semin Thromb Hemost; 2005 Apr; 31(2):195-204. PubMed ID: 15852223
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Langille J; Harwig C; Veale D; Yang W; Li T; Zhu Y; Bey M; Baird I; Sartori M; Metz M; Mosi R; Nelson K; Bodart V; Wong R; Fricker S; Mac Farland R; Huskens D; Schols D
Bioorg Med Chem Lett; 2011 Dec; 21(23):6950-4. PubMed ID: 22033460
[TBL] [Abstract][Full Text] [Related]
29. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
Imada T; Cho N; Imaeda T; Hayase Y; Sasaki S; Kasai S; Harada M; Matsumoto H; Endo S; Suzuki N; Furuya S
J Med Chem; 2006 Jun; 49(13):3809-25. PubMed ID: 16789738
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
33. A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.
Bach P; Boström J; Brickmann K; van Giezen JJ; Hovland R; Petersson AU; Ray A; Zetterberg F
Bioorg Med Chem Lett; 2011 May; 21(10):2877-81. PubMed ID: 21507636
[TBL] [Abstract][Full Text] [Related]
34. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
36. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
37. Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists.
Tamayo NA; Bo Y; Gore V; Ma V; Nishimura N; Tang P; Deng H; Klionsky L; Lehto SG; Wang W; Youngblood B; Chen J; Correll TL; Bartberger MD; Gavva NR; Norman MH
J Med Chem; 2012 Feb; 55(4):1593-611. PubMed ID: 22329507
[TBL] [Abstract][Full Text] [Related]
38. Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
Watson RJ; Allen DR; Birch HL; Chapman GA; Hannah DR; Knight RL; Meissner JW; Owen DA; Thomas EJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6806-10. PubMed ID: 17964154
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
